Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.

@article{Bhindi2017OncologicOF,
  title={Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.},
  author={Bimal Bhindi and Igor Frank and Ross J Mason and Robert F. Tarrell and Prabin Thapa and John C. Cheville and Brian Addis Costello and Lance C. Pagliaro and Robert Jeffrey Karnes and Robert Thompson and Matthew K. Tollefson and Stephen Anthony Boorjian},
  journal={European urology},
  year={2017},
  volume={72 5},
  pages={
          660-664
        }
}
While it has been demonstrated that receipt of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) improves survival compared to RC alone, the driving factor for this benefit may be from patients with ypT0 status at surgery. Meanwhile, the implications of having residual urothelial carcinoma of the bladder (rUCB) at RC after NAC are less clear. We therefore evaluated whether survival differed between patients with rUCB at RC after NAC and stage-matched controls who underwent RC alone… CONTINUE READING
3 Citations
12 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapybased strategy for muscle-invasive urothelial carcinoma of the bladder

  • T Seisen, G Sonpavde, N Kachroo
  • Eur Urol Suppl 2017;16:e291
  • 2017
1 Excerpt

Similar Papers

Loading similar papers…